Day 4 Recap: AAD 2025

To stay informed with the latest conference insights, subscribe to receive our eNewsletters.

Biologic-Naïve Patients with Psoriasis Have a Reduced Risk of Psoriatic Arthritis, Based on NPF Target Goals

According to a poster from AAD, the National Psoriasis Foundation’s treatment goals were used as a benchmark to determine the risk of developing psoriatic arthritis after initiating biologics.

Peter Lio, MD: Minimizing Discomfort in Dermatologic Procedures

Lio shared insights on minimizing pain in dermatologic procedures, highlighting practical techniques from his AAD 2025 presentations.

Breakthrough Therapies in Itch Management: Insights From Brian S. Kim, MD, FAAD

Brian S. Kim, MD, FAAD, shares itch research updates at the AAD Annual Meeting.

Jeff Stark, MD: Discussing Bimzelx’s Efficacy and Future in Treating Inflammatory Skin Diseases

Stark highlighted Bimzelx’s role in treating psoriasis and HS, introduced the BE BOLD study for PsA, and looked to future innovation in inflammatory skin disease.

Expert Insights Into L'Oréal’s Voluntary Recall of Benzoyl Peroxide Products

Christopher Bunick, MD, PhD, explains what comes next for clinicians and patients live at AAD 2025.

Michael Gold, MD: Insights on Silicone, Energy-Based Devices, and Radiation Therapy

Gold discussed breakthrough treatments for scars, including silicone, energy-based devices, and radiation therapy.

How to Avoid Complications With Radiofrequency and Ultrasound-Based Technologies

At AAD 2025, Karan Lal, DO, MS, FAAD, presented clinical insights on insulated microneedling tips, grounding pad issues in monopolar radiofrequency, and more.

Stay tuned for more expert insights, clinical research, and late-breaking data from AAD 2025.